Kyverna Therapeutics (KYTX) Retained Earnings (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Retained Earnings came in at -$464.6 million in Q1 2026, down 50.77% YoY from -$943.7 million in Q1 2025, and down 9.36% on a QoQ basis from -$424.8 million in Q4 2025.
Kyverna Therapeutics (KYTX) Retained Earnings (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Retained Earnings data on file, last reported at -$464.6 million in Q1 2026.
- Quarterly Retained Earnings fell 50.77% year-over-year to -$464.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$464.6 million (down 50.77% YoY) and the FY2025 annual result came in at -$424.8 million, down 61.21% from the prior year.
- Retained Earnings eased to -$464.6 million in Q1 2026, from -$424.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1000.0 in Q1 2024 to a low of -$464.6 million in Q1 2026.
- A 4-year average of -$256.0 million and a median of -$285.8 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings slumped 30815400.0% — and 2026, when it slumped 50.77%.
- Tracing KYTX's Retained Earnings over 4 years: stood at -$136.0 million in 2023, then sank by 93.7% to -$263.5 million in 2024, then tumbled by 61.21% to -$424.8 million in 2025, then declined by 9.36% to -$464.6 million in 2026.
- The last three Retained Earnings figures came in at -$464.6 million (Q1 2026), -$424.8 million (Q4 2025), and -$387.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -502.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -502.90 Mn |
| Mar 31, 2026 | -464.60 Mn |
| Dec 31, 2025 | -424.83 Mn |
| Sep 30, 2025 | -387.00 Mn |
| Jun 30, 2025 | -350.24 Mn |
| Mar 31, 2025 | -308.16 Mn |
| Dec 31, 2024 | -263.52 Mn |
| Sep 30, 2024 | -226.00 Mn |
| Jun 30, 2024 | -37,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -136.04 Mn |